EMZOR TO CONSTRUCT US$$23M API FACILITY IN NIGERIA

Emzor Pharmaceuticals’ $23 million investment in constructing an Active Pharmaceutical Ingredients (API) facility in Sagamu, Ogun State, reflects a significant commitment to combating malaria in Nigeria and sub-Saharan Africa. The initiative, aimed at enabling local production of essential pharmaceutical ingredients for anti-malarial drugs, promises to strengthen the region’s anti-malarial supply chain and expand pharmaceutical manufacturing capacity.

By aligning with Sustainable Development Goal 3, Emzor’s efforts aim to contribute to longer and healthier lives for all, particularly in Africa. The establishment of the API plant underscores the company’s commitment to financial inclusion and the health of pregnant women by producing APIs for manufacturing anti-malarial pharmaceuticals, including those for the Intermittent Preventive Treatment of malaria in pregnancy.

Upon completion, the API facility will be the first of its kind in Nigeria and Africa, with an expected annual production capacity of 400 metric tonnes of quality APIs. This significant milestone is expected to accelerate the fight against malaria on the continent.

The funding support from the European Investment Bank (EIB), announced during the EU-Nigeria Strategic Dialogue last October, further underscores the importance of the project in advancing healthcare in Africa. The project aims to reduce Nigeria’s reliance on imported APIs and focus on producing high-quality and affordable anti-malarial drugs, marking a pivotal advancement in Africa’s healthcare sector.

Emzor Pharmaceuticals’ partnership with India’s Mangalam Drugs and Organics Limited for technology transfer training, testing, and initial production at the site demonstrates its commitment to leveraging global expertise and resources to address regional health challenges effectively.

SOURCE: Vanguard